Supported by National Institute of Health


NIH support came as a R13 grant. Dr Franceschini is the PI of that grant and she is running the conference. Hence she has to disclose her conflict of interest.
Dr. Maria A. Franceschini has a financial interest in 149 Medical, Inc. This company is developing diffuse correlation spectroscopy (DCS) technology for assessing and monitoring cerebral blood flow (CBF) in newborn infants. Dr. Franceschini’s interests were reviewed and are managed by Mass General Hospital, and Mass General Brigham in accordance with their conflict of interest policies
Exhibitors
SOLD OUT
for waiting list

Artinis
Biopac
Boston Electronics
Cortivision
Gowerlabs
ISS
Hamamatsu
Neuluce
NIRx
Obelab
OptoElectronics Components
PioNIRS
Rogue
Seenel Imaging
Spectratech/VOX Biomedical
TechEn
